RTW Investments’s Lipocine LPCN Stock Holding History

RTW Investments’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-14,143	Closed	-$2.44M	–	38
2016 Q1	$2.44M	Buy	14,143 +1,172	+9%	+$200K	0.89%	22
2015 Q4	$2.85M	Buy	12,971 +471	+4%	+$98.8K	0.93%	19
2015 Q3	$2.51M	Buy	12,500 +186	+2%	+$43K	0.78%	22
2015 Q2	$1.8M	Hold	12,314	–	–	0.52%	25
2015 Q1	$1.44M	Hold	12,314	–	–	0.65%	18
2014 Q4	$1.1M	Buy	+12,314	New	+$1.04M	0.41%	19

Other funds holding LPCN

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

RTW Investments's LPCN Position: Q2 2016 in Review

RTW Investments sold out of Lipocine (LPCN) in Q2 2016, closing a stake of 14,143 shares — an estimated $2.44M sold.

RTW Investments first reported a position in LPCN in Q4 2014 and held it in 6 quarters. The position peaked at $2.85M in Q4 2015. 54 funds tracked by Wall St. Rank hold LPCN as of Q2 2016.

RTW Investments reported no remaining Lipocine position as of Q2 2016 after selling out during the quarter.
RTW Investments sold 14,143 Lipocine shares in Q2 2016, an estimated $2.44M.
RTW Investments first reported a position in Lipocine in Q4 2014 and held it in 6 quarters.
RTW Investments's Lipocine position peaked at $2.85M in Q4 2015.
54 funds tracked by Wall St. Rank held Lipocine as of Q2 2016.

Based on RTW Investments's 13F filing for Q2 2016, filed 15 Aug 2016.